Evaluation of the efficacy of probiotic medicines including in the therapy of patients with post-infectious irritable bowel syndrome after COVID-19 infection surviving
- Authors: Didigova R.T.1, Evloeva D.A.1, Ugurchieva P.O.1, Malsagova I.Y.1, Khamkhoeva F.M.1, Bokova M.D.1
-
Affiliations:
- Ingush State University
- Issue: Vol 9, No 2 (2023)
- Pages: 154-157
- Section: ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT
- URL: https://journals.rcsi.science/2412-4036/article/view/258861
- DOI: https://doi.org/10.18565/therapy.2023.2.154–157
- ID: 258861
Cite item
Open Access
Access granted
Subscription Access
Abstract
Nowadays is getting to be more and more evidentiary material accumulation regarding the direct and indirect influence of gut microbiota at the irritable bowel syndrome (IBS) development.
The aim of the research is to estimate the efficacy of including probiotic medicaments in the treatment of patients with post-infectious IBS (PI-IBS) after suffering from COVID-19.
Material and methods. 64 patients with PI-IBS syndrome developed after suffering from COVID-19, who were treated in a medical facility in the Republic of Ingushetia were examined.
Results. Patients of the main group, who had probiotics included in IBS therapy, had a higher frequency of getting rid of the clinical manifestations of the disease. The efficacy of treatment (indicators of reducing the severity of IBS symptoms) was 84% in the main group versus 60% in the comparison group. Intergroup comparison showed a significantly higher overall efficacy of therapy in the main group comparatively to the comparison group.
Conclusion. The main criterion for the efficacy of the inclusion of probiotics in therapy was the dynamics of IBS gastrointestinal symptoms (bloating, abdominal pain, discomfort, frequency and nature of stools) and quality of life. As the results of the study showed, the proportion of participants who noted an improvement of their condition in terms of the general indicator of abdominal discomfort, in the second week of the study, was significantly higher in the main group, who received probiotics as part of complex therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Roza T. Didigova
Ingush State University
Email: roza2007@mail.ru
MD, professor, head of the Department «Hospital Therapy»
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasDina A. Evloeva
Ingush State University
Email: roza2007@mail.ru
MD, professor of the Department «Hospital Therapy»
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasPyatimat O. Ugurchieva
Ingush State University
Email: roza2007@mail.ru
senior lecturer at the Department «Hospital Therapy»
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasInna Ya. Malsagova
Ingush State University
Email: roza2007@mail.ru
PhD in Medical Sciences, associate professor of the Department «Hospital Therapy»
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasFerdovs M.-B. Khamkhoeva
Ingush State University
Email: roza2007@mail.ru
PhD in Medical Sciences, associate professor of the Department «Hospital Therapy»
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasMadina D. Bokova
Ingush State University
Author for correspondence.
Email: roza2007@mail.ru
6th year student of the Faculty of general medicine
Russian Federation, 7, I. Zyablikova Avenue, 386001 MagasReferences
- Гаус О.В., Ливзан М.А. Синдром раздраженного кишечника: что нового? (Обзор материалов UEG Week Virtual 2020). Медицинский алфавит. 2021; (6): 41-47. [Gaus O.V., Livzan M.A. Irritable bowel syndrome: What’s new? (UEG Week Virtual 2020 materials review). Meditsinskiy alfavit = Medical Alphabet. 2021; (6): 41-47 (In Russ.)]. https://dx.doi.org/10.33667/2078-5631-2021-6-41-47. EDN: JXGDKR.
- Гаус О.В., Ливзан М.А. «Гастроинтестинальная» коморбидность при синдроме раздраженного кишечника. Экспериментальная и клиническая гастроэнтерология. 2021; (6): 104-111. [Gaus O.V., Livzan M.A. «Gastrointestinal» comorbidity in irritable bowel syndrome. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; (6): 104-111 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-190-6-104-111. EDN: LDTXYP.
- Гаус О.В., Ливзан М.А., Турчанинов Д.В. с соавт. Абдоминальная боль у лиц молодого возраста. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31(3): 25-35. [Gaus O.V., Livzan M.A., Turchaninov D.V. et al. Abdominal pain in young adults. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021; 31(3): 25-35 (In Russ.)]. https://dx.doi.org/10.22416/1382-4376-2021-31-3-26-35. EDN: VZZANF.
- Ивашкин В.Т., Маев И.В., Шелыгин Ю.А. с соавт. Диагностика и лечение синдрома раздраженного кишечника (клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31(5): 74-95. [Ivashkin V.T., Mayev I.V., Shelygin Yu.A. et al. Diagnosis and treatment of irritable bowel syndrome (Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021; 31(5): 74-95 (In Russ.)]. https://dx.doi.org/10.22416/1382-4376-2021-31-5-74-95. EDN: MKBDEB.
- Lozupone C.A., Stombaugh J.I., Gordon J.I. et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012; 489(7415): 220-30. https://dx.doi.org/10.1038/nature11550.
- Grenham S., Clarke G., Cryan J.F. et al. Brain-gut-microbe communication in health and disease. Front Physiol. 2011; 2: 94. https://dx.doi.org/10.3389/fphys.2011.00094.
- Bellini M., Gambaccini D., Stasi C. et al. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014; 20(27): 8807-20. https://dx.doi.org/10.3748/wjg.v20.i27.8807.
- Tap J., Derrien M., Tornblom H. et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017; 152(1): 111-23.e8. https://dx.doi.org/10.1053/j.gastro.2016.09.049.
- Rajilic-Stojanovic M., Biagi E., Heilig H.G. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011; 141(5): 1792-801. https://dx.doi.org/10.1053/j.gastro.2011.07.043.
Supplementary files
